questionText: To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients in Essex with HER2-low metastatic breast cancer who would be eligible for treatment with Enhertu were it to be routinely commissioned.
answerText: In July 2024, the National Institute for Health and Care Excellence (NICE) estimated that approximately 1,000 to 1,500 people would have been eligible for treatment with trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cance...
heading: Breast Cancer: Essex